Jeremiah Sparks, Sr. Director of Commercialization
AVITA Medical is a global regenerative medicine company that is transforming lives through its novel approach to skin regeneration. In the U.S., the company’s RECELL System innovates the treatment of thermal burns by harvesting a small amount of a patient’s own skin to prepare Spray-On Skin™ Cells at the point of care in as little as 30 minutes.
The RECELL System requires substantially less donor skin than is required for conventional split-thickness autografts to achieve closure of burn wounds. Patients experience fast donor site healing with less pain, substantially lower treatment costs, and shorter lengths of stay. While RECELL launched in the U.S. in September 2018, it has been used since 2017 to treat more than 155 burn patients under the FDA’s Compassionate Use and Continued Access programs. Worldwide, over 7,000 patients have been treated with the RECELL System to date.
Clinical studies show that RECELL significantly reduced donor site size requirements, with a 97.5% reduction for deep partial-thickness burns and a 32% reduction for mixed-depth burns when used in combination with a split-thickness skin graft.
Other donor site outcomes include two times greater healing at week 1, reduced scarring for all time points, reduced patient-reported pain by 50% through week 8, and improved patient satisfaction with the scar appearance. RECELL also achieved comparable wound closure rates at the treatment site while requiring much less donor skin.
Numerous case studies demonstrate fast and robust epidermal regeneration, superior donor site healing, and reduced scarring achieved with RECELL.